Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
FCGR2A 2212 CETUXIMAB CHEMBL1201577 DrugBank 17139284, 17016423, 17704420
FCGR2A 2212 ETANERCEPT CHEMBL1201572 DrugBank 15526004, 15457442
FCGR2A 2212 ABCIXIMAB CHEMBL1201584 DrugBank 17139284, 17016423
FCGR2A 2212 GEMTUZUMAB OZOGAMICIN CHEMBL1201506 DrugBank 17139284, 17016423
FCGR2A 2212 EFALIZUMAB CHEMBL1201575 DrugBank 17139284, 17016423
FCGR2A 2212 NATALIZUMAB CHEMBL1201607 DrugBank 17139284, 17016423
FCGR2A 2212 BEVACIZUMAB CHEMBL1201583 DrugBank 17139284, 17016423
FCGR2A 2212 ADALIMUMAB CHEMBL1201580 DrugBank 17139284, 17016423
FCGR2A 2212 CYCLOPHOSPHAMIDE CHEMBL88 PharmGKB
FCGR2A 2212 PACLITAXEL CHEMBL428647 PharmGKB
FCGR2A 2212 ALEFACEPT CHEMBL1201571 DrugBank 17139284, 17016423
FCGR2A 2212 PALIVIZUMAB CHEMBL1201586 DrugBank 17139284, 17016423
FCGR2A 2212 DACLIZUMAB CHEMBL1201605 DrugBank 17139284, 17016423
FCGR2A 2212 GLOBULIN, IMMUNE CHEMBL1201599 antagonist DrugBank 20441428, 17911465, 17351760
FCGR2A 2212 TRASTUZUMAB CHEMBL1201585 PharmGKB, DrugBank 17139284, 17016423, 17704420
FCGR2A 2212 BASILIXIMAB CHEMBL1201439 DrugBank 17139284, 17016423
FCGR2A 2212 MUROMONAB-CD3 CHEMBL1201608 DrugBank 17139284, 17016423
FCGR2A 2212 IBRITUMOMAB TIUXETAN CHEMBL1201606 DrugBank 17139284, 17016423
FCGR2A 2212 TOSITUMOMAB CHEMBL1201604 DrugBank 17139284, 17016423
FCGR2A 2212 ALEMTUZUMAB CHEMBL1201587 DrugBank 15217834
FCGR2A 2212 THIOLACTOMYCIN CHEMBL399043 antagonist TTD
FCGR2A 2212 RITUXIMAB CHEMBL1201576 DrugBank 16609067, 17324336

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
FCGR2A rs1801274 AA cyclophosphamide efficacy yes Genotype AA is associated with increased response to cyclophosphamide, doxorubicin, paclitaxel and trastuzumab in women with Breast Neoplasms as compared to genotypes AG + GG. 21109570 827825723
FCGR2A rs1801274 G infliximab efficacy yes Association only existing for the time point at 3 month but not for later time points 6 and 12 month. Response was determined using European League Against Rheumatism (EULAR) criteria. Allele G is associated with decreased response to infliximab in people with Arthritis, Rheumatoid as compared to allele A. 24667440 1184169928
FCGR2A rs1801274 A adalimumab efficacy yes as measured by DAS28 after 14 weeks treatment. Allele A is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to allele G. 25823785 1447944531
FCGR2A rs1801274 AG + GG Tumor necrosis factor alpha efficacy yes This was only significant in patients with follow-up times greater than or equal to 6 months. Association is stated in text and abstract as for RR + RH genotype shown here as GG+AG (although table 4 and figure 2 have HH and HR as associated). Genotypes AG + GG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Psoriatic, Crohn Disease, Psoriasis and Spondylitis, Ankylosing as compared to genotype AA. 27490376 1448259064
FCGR2A rs1801274 A Tumor necrosis factor alpha efficacy no Moderate to severe chronic plaque psoriasis. Responders were defined as those with a change in the Psoriasis Area and Severity Index (PASI) of >75%, while non-responders were defined as those with a change in PASI of <=50%, after 6 months of therapy. No association was found between any of the genotypes (AA, AG, GG) and response to anti-TNF therapy. Please note that alleles have been complemented to the plus chromosomal strand. Allele A is not associated with response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to allele G. 27044681 1448426957
FCGR2A rs1801274 GG cetuximab efficacy yes ONLY significant when combined in an analysis with rs396991. The median progression-free survival time for patients with the rs1801274 GG genotype and/or the rs396991 TT genotype was significantly longer as compared with carriers of rs1801274 A allele and/or rs396991 G allele (5.5 vs 4.1 months). This association remained significant in Cox multivariate analysis. However, on its own, this SNP was NOT significantly associated with progression-free survival time. Patients received polychemotherapy with cisplatin or carboplatin, fluorouracil and cetuximab and had metastatic squamous cell head and neck cancer. Genotype GG is associated with increased response to cetuximab in people with Head and Neck Neoplasms as compared to genotypes AA + AG. 28719596 1449154934
FCGR2A rs1801274 AA cetuximab efficacy yes Overall survival and progression-free survival were used as indicators of response to cetuximab. Genotype AA is associated with increased response to cetuximab in people with Colorectal Neoplasms as compared to genotypes AG + GG. 30318772 1449752258
FCGR2A rs1801274 AA rituximab efficacy yes The AA genotype was associated with improved EULAR response and improved remission at 6 months, improved EULAR response and improvement in DAS28 at 12 months and improvements EULAR response and DAS28 at 18 months. Please note that alleles have been complemented to the positive strand. Genotype AA is associated with increased response to rituximab in people with Arthritis, Rheumatoid as compared to genotypes AG + GG. 30457672 1450371578
FCGR2A rs1801274 A tocilizumab efficacy yes Allele A is not associated with response to tocilizumab in people with Arthritis, Rheumatoid as compared to allele G. 30457672 1450371564
FCGR2A rs1801274 GG adalimumab efficacy no After 12 weeks of treatment, no significant differences in mean percentage Psoriasis Area and Severity Index (PASI) improvement, percentage of patients with an improvement of PASI of at least 75%, percentage of patients with a worsening of PASI or an improvement of less than 50%, or PASI after 12 weeks of treatment were seen between the genotypes. Genotype GG is not associated with response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AA + AG. 24048425 1183699535
FCGR2A rs1801274 GG adalimumab efficacy yes Patients with the GG genotype had a higher psoriasis body surface area (BSA) after 6-8 weeks of treatment, as compared to those with the AA or AG genotype. No significant difference in psoriasis BSA were seen after 12 weeks of treatment. Additionally, no significant differences between these genotype groups were seen when considering the mean percentage psoriasis body surface area (BSA) improvement over 12 weeks. Genotype GG is associated with decreased response to adalimumab, etanercept or infliximab in people with Psoriasis as compared to genotypes AA + AG. 24048425 1183699530
FCGR2A rs1801274 AA trastuzumab efficacy no However, the difference was not statistically significant. The response rates are 70% for H/H (AA genotype), 44% for H/R (AG) and 40% for RR patients. Genotype AA is associated with increased response to trastuzumab in people with Breast Neoplasms as compared to genotypes AG + GG. 18347005 1185003550
FCGR2A rs1801274 G cetuximab efficacy no Meta-analysis with 15 studies. The authors did not provide the exact number of patients but stated that "the median number of patients per analysis was 110 (range 50 - 740)". Most definitions of response were variations of the RECIST criteria. Please note that alleles have been complemented to the plus chromosomal strand. Allele G is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to allele A. 27897268 1449165374